| WB | 1/500 - 1/2000 | Human,Mouse,Monkey,Rat |
| IF | 咨询技术 | Human,Mouse,Monkey,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Monkey,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Monkey,Rat |
| FCM | 咨询技术 | Human,Mouse,Monkey,Rat |
| Elisa | 1/10000 | Human,Mouse,Monkey,Rat |
| Aliases | CD25; IL2R; TCGFR; IDDM10 |
| Entrez GeneID | 3559 |
| clone | 1B5D12 |
| WB Predicted band size | 30.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Monkey,Rat |
| Immunogen | Purified recombinant fragment of human IL2RA (AA: 34-139) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
1. **"IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility"**
- **作者**: Smyth DJ, et al.
- **摘要**: 该研究通过全基因组关联分析，揭示了IL2RA基因多态性与1型糖尿病和多发性硬化的遗传关联，表明IL2RA在自身免疫调节中的关键作用，其抗体可能影响T细胞活化和疾病风险。
2. **"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells"**
- **作者**: Fontenot JD, et al.
- **摘要**: 文章利用IL2RA(CD25)抗体研究调节性T细胞(Treg)功能，证明IL2RA信号对Treg的发育和免疫抑制功能至关重要，阻断该受体可破坏免疫耐受。
3. **"Blockade of IL2RA promotes tumor control by expanding tumor-reactive CD8+ T cells"**
- **作者**: Lopes J, et al.
- **摘要**: 研究发现抗IL2RA抗体通过抑制调节性T细胞活性，增强CD8+ T细胞的抗肿瘤免疫应答，为癌症免疫治疗提供了新策略。
4. **"Regulatory T cell responses in participants with autoimmune diseases treated with anti-CD25 antibody"**
- **作者**: Saadoun D, et al.
- **摘要**: 临床试验显示，抗CD25抗体(如达利珠单抗)可选择性耗竭活化T细胞，抑制自身免疫反应，但长期治疗可能引发免疫失衡风险。
The interleukin-2 receptor alpha (IL2RA), also known as CD25. is a key component of the high-affinity IL-2 receptor complex, which regulates immune cell activation and tolerance. Primarily expressed on regulatory T cells (Tregs), activated effector T cells, and some B cells, IL2RA binds IL-2 to facilitate signaling through the JAK-STAT pathway, critical for T cell proliferation, survival, and immune homeostasis. Dysregulation of IL2RA is implicated in autoimmune diseases (e.g., type 1 diabetes, multiple sclerosis) and cancers, making it a therapeutic and diagnostic target.
IL2RA-specific antibodies are widely used in research and clinical applications. In research, they help identify and isolate Tregs or activated T cells via flow cytometry or immunohistochemistry. Therapeutically, monoclonal antibodies like basiliximab and daclizumab (now withdrawn) were designed to block IL-2 signaling by targeting IL2RA, preventing T cell activation in organ transplantation and autoimmune conditions. However, their use highlighted complexities: while suppressing pathogenic T cells, they may also inhibit Treg function, potentially compromising immune balance. Additionally, IL2RA autoantibodies serve as biomarkers in autoimmune diseases. Ongoing studies explore engineered IL2RA-targeting agents to selectively modulate Tregs or effector T cells, aiming for precision immunotherapy with fewer off-target effects.
×
